NASDAQ:LUNG

Pulmonx (LUNG) Stock Forecast, Price & News

$10.04

-0.29 (-2.81%)

(As of 02:44 PM ET)

Compare

Today's Range: $10.00
▼
$10.34
50-Day Range: $9.88
▼
$14.00
52-Week Range: $4.07
▼
$18.18

Volume: 73,680 shs
Average Volume: 342,737 shs
Market Capitalization: $381.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Pulmonx MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.57 Rating Score
Upside/Downside: 48.5% Upside
$15.00 Price Target
Short Interest: Healthy
3.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.17
Based on 5 Articles This Week
Insider Trading: Selling Shares
$388,865 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.69) to ($1.64) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

515th out of 969 stocks

Surgical & Medical Instruments Industry

59th out of 100 stocks

3.3

Analyst's Opinion

Consensus Rating
Pulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, Pulmonx has a forecasted upside of 48.5% from its current price of $10.10.
Amount of Analyst Coverage
Pulmonx has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.87% of the float of Pulmonx has been sold short.
Short Interest Ratio / Days to Cover
Pulmonx has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Pulmonx has recently decreased by 2.38%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Pulmonx does not currently pay a dividend.
Dividend Growth
Pulmonx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LUNG.

2.3

News and Social Media Coverage

News Sentiment
Pulmonx has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Pulmonx this week, compared to 1 article on an average week.
Search Interest
2 people have searched for LUNG on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Pulmonx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pulmonx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $388,865.00 in company stock.
Percentage Held by Insiders
Only 5.70% of the stock of Pulmonx is held by insiders.
Percentage Held by Institutions
88.09% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Pulmonx are expected to grow in the coming year, from ($1.69) to ($1.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pulmonx is -6.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pulmonx is -6.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pulmonx has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pulmonx (NASDAQ:LUNG) Stock

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.

LUNG Price History

30 days | 90 days | 365 days | Advanced Chart

LUNG Stock News Headlines

October 2, 2023 | americanbankingnews.com

Pulmonx Co. (NASDAQ:LUNG) Given Consensus Recommendation of "Moderate Buy" by Brokerages

October 1, 2023 | americanbankingnews.com

Head to Head Contrast: Pulmonx (NASDAQ:LUNG) versus TearLab (OTCMKTS:TEAR)

October 2, 2023 | Oxford Club (Ad)

Better Than Oil Stocks

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

September 25, 2023 | abcnews.go.com

Iowa Gov. Kim Reynolds says her husband has lung cancer

September 6, 2023 | nasdaq.com

Craig-Hallum Initiates Coverage of Pulmonx (LUNG) with Buy Recommendation

September 5, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Pulmonx (LUNG), Omnicell (OMCL)

August 4, 2023 | msn.com

Piper Sandler Maintains Pulmonx (LUNG) Overweight Recommendation

August 3, 2023 | markets.businessinsider.com

Pulmonx (LUNG) Receives a Sell from Bank of America Securities

October 2, 2023 | Oxford Club (Ad)

Better Than Oil Stocks

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

August 2, 2023 | finance.yahoo.com

Pulmonx Reports Second Quarter 2023 Financial Results

July 26, 2023 | finance.yahoo.com

Pulmonx to Present at the Canaccord Genuity 43rd Annual Growth Conference

July 17, 2023 | finance.yahoo.com

Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023

July 11, 2023 | msn.com

Citigroup Maintains Pulmonx (LUNG) Buy Recommendation

July 11, 2023 | benzinga.com

Citigroup Maintains Buy on Pulmonx, Raises Price Target to $16

July 10, 2023 | finance.yahoo.com

Shareholders in Pulmonx (NASDAQ:LUNG) are in the red if they invested a year ago

June 23, 2023 | msn.com

Pulmonx: Entry To Japan Market Bullish For Zephyr Volumes (Rating Upgrade)

May 4, 2023 | finanznachrichten.de

Pulmonx Corporation: Pulmonx Reports First Quarter 2023 Financial Results

May 4, 2023 | msn.com

Citigroup Maintains ProLung (LUNG) Buy Recommendation

May 3, 2023 | msn.com

Morgan Stanley Maintains ProLung (LUNG) Equal-Weight Recommendation

May 3, 2023 | msn.com

Piper Sandler Maintains ProLung (LUNG) Overweight Recommendation

May 3, 2023 | markets.businessinsider.com

7 Analysts Have This to Say About Pulmonx

May 2, 2023 | finance.yahoo.com

Pulmonx Reports First Quarter 2023 Financial Results

May 1, 2023 | benzinga.com

A Preview Of Pulmonx's Earnings

April 25, 2023 | finance.yahoo.com

Pulmonx to Present at the Bank of America Securities 2023 Health Care Conference

April 18, 2023 | finance.yahoo.com

Pulmonx to Report First Quarter 2023 Financial Results on May 2, 2023

April 17, 2023 | finance.yahoo.com

Pulmonx Corporation (NASDAQ:LUNG) Not Flying Under The Radar

April 9, 2023 | benzinga.com

Pulmonx Corp (LUNG) Stock: What Does the Chart Say Thursday?

See More Headlines

Receive LUNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter.

LUNG Company Calendar

Last Earnings: 8/02/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LUNG
CUSIP: N/A
CIK: 1127537
Web: pulmonx.com
Phone: 1-650-364-0400
Fax: N/A
Employees: 269
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.00
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +49.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.57
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,920,000.00
Net Margins: -99.76%
Pretax Margin: -98.92%
Return on Equity: -40.65%
Return on Assets: -30.63%

Debt

Debt-to-Equity Ratio: 0.28
Current Ratio: 8.42
Quick Ratio: 7.62

Sales & Book Value

Annual Sales: $53.66 million
Price / Sales: 7.12
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.12 per share
Price / Book: 2.44

Miscellaneous

Outstanding Shares: 38,030,000
Free Float: 35,860,000
Market Cap: $381.82 million
Optionable: Not Optionable
Beta: 0.44

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Glendon E. French (Age 61)
CEO, Pres & Director
Comp: $892.29k

Mr. David A. Lehman (Age 62)
Gen. Counsel & Sec.
Comp: $571.59k

Mr. Geoffrey Beran Rose (Age 49)
Chief Commercial Officer
Comp: $560.28k

Dr. Derrick Sung Ph.D. (Age 50)
Chief Financial Officer

Mr. Sri Radhakrishnan
Chief Technical Officer

Ms. Marcee M. Maroney (Age 53)
VP of Marketing

Sarah Huber
VP of Sales (U.S.)

Ms. Lisa Paul (Age 59)
Chief People Officer

Mr. Jérôme Erath
Sr. VP & GM of Europe Middle-East & Africa

Mr. John B. McKune (Age 47)
VP & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LUNG Stock - Frequently Asked Questions

Should I buy or sell Pulmonx stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LUNG shares.
View LUNG analyst ratings or view top-rated stocks.
What is Pulmonx's stock price forecast for 2023?: 7 equities research analysts have issued 1 year target prices for Pulmonx's shares. Their LUNG share price forecasts range from $8.00 to $20.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 49.4% from the stock's current price.
View analysts price targets for LUNG or view top-rated stocks among Wall Street analysts.
How have LUNG shares performed in 2023?: Pulmonx's stock was trading at $8.43 at the start of the year. Since then, LUNG shares have increased by 19.1% and is now trading at $10.04.
View the best growth stocks for 2023 here.
When is Pulmonx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our LUNG earnings forecast.
How were Pulmonx's earnings last quarter?: Pulmonx Co. (NASDAQ:LUNG) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). The company had revenue of $17.20 million for the quarter, compared to the consensus estimate of $15.86 million. Pulmonx had a negative trailing twelve-month return on equity of 40.65% and a negative net margin of 99.76%. Pulmonx's revenue for the quarter was up 23.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.40) EPS.
What guidance has Pulmonx issued on next quarter's earnings?: Pulmonx updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $64.00 million-$66.00 million, compared to the consensus revenue estimate of $64.81 million.

When did Pulmonx IPO?: (LUNG) raised $100 million in an initial public offering on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.
What is Pulmonx's stock symbol?: Pulmonx trades on the NASDAQ under the ticker symbol "LUNG."
How do I buy shares of Pulmonx?: Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pulmonx's stock price today?: One share of LUNG stock can currently be purchased for approximately $10.04.
How much money does Pulmonx make?: Pulmonx (NASDAQ:LUNG) has a market capitalization of $381.82 million and generates $53.66 million in revenue each year. The company earns $-58,920,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis.
How many employees does Pulmonx have?: The company employs 269 workers across the globe.
How can I contact Pulmonx?: The official website for the company is pulmonx.com. The company can be reached via phone at 1-650-364-0400 or via email at investors@pulmonx.com.

This page (NASDAQ:LUNG) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial